Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H (April 1992). „Structure and expression of a human oxytocin receptor”. Nature356 (6369): 526–9. DOI:10.1038/356526a0. PMID1313946.
Veenema AH, Neumann ID (2008). „Central vasopressin and oxytocin release: regulation of complex social behaviours”. Progress in Brain Research170: 261–76. DOI:10.1016/S0079-6123(08)00422-6. PMID18655888.
Chini B, Manning M (August 2007). „Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges”. Biochemical Society Transactions35 (Pt 4): 737–41. DOI:10.1042/BST0350737. PMID17635137.
Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G (2008). „Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents”. Progress in Brain Research170: 473–512. DOI:10.1016/S0079-6123(08)00437-8. PMID18655903.
Wyatt PG, Allen MJ, Chilcott J, Foster A, Livermore DG, Mordaunt JE, Scicinski J, Woollard PM (May 2002). „Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives”. Bioorganic & Medicinal Chemistry Letters12 (10): 1399–404. DOI:10.1016/S0960-894X(02)00159-2. PMID11992786.
Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosenzweig-Lipson S (April 2006). „Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications”. Psychopharmacology (Berlin)185 (2): 218–25. DOI:10.1007/s00213-005-0293-z. PMID16418825.
google.com
Rahman Z, Resnick L, Rosenzweig-Lipson SJ, Ring RH,"Methods of treatment using oxytocin receptor agonists", US patent application 2007/0117794, published 24. 5. 2007. , assigned to Wyeth Corp
Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H (April 1992). „Structure and expression of a human oxytocin receptor”. Nature356 (6369): 526–9. DOI:10.1038/356526a0. PMID1313946.
Veenema AH, Neumann ID (2008). „Central vasopressin and oxytocin release: regulation of complex social behaviours”. Progress in Brain Research170: 261–76. DOI:10.1016/S0079-6123(08)00422-6. PMID18655888.
Chini B, Manning M (August 2007). „Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges”. Biochemical Society Transactions35 (Pt 4): 737–41. DOI:10.1042/BST0350737. PMID17635137.
Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G (2008). „Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents”. Progress in Brain Research170: 473–512. DOI:10.1016/S0079-6123(08)00437-8. PMID18655903.
Wyatt PG, Allen MJ, Chilcott J, Foster A, Livermore DG, Mordaunt JE, Scicinski J, Woollard PM (May 2002). „Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives”. Bioorganic & Medicinal Chemistry Letters12 (10): 1399–404. DOI:10.1016/S0960-894X(02)00159-2. PMID11992786.
Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosenzweig-Lipson S (April 2006). „Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications”. Psychopharmacology (Berlin)185 (2): 218–25. DOI:10.1007/s00213-005-0293-z. PMID16418825.